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ABSTRACT
Inactivation of tumor suppressor genes plays an im-
portant role in tumorigenesis, and epigenetic modi-
fications such as DNA methylation are frequently
associated with transcriptional repression. Here,
we show that gene silencing at selected genes
with signs of DNA hypermethylation in breast
cancer cells involves Pol II stalling. We studied
several repressed genes with DNA hypermethylation
within a region 1-kb upstream of the transcriptional
start site that were upregulated after treatment with
DNA demethylating agents, such as Azacytidine and
several natural products. All those selected genes
had stalled Pol II at their transcriptional start site
and showed enhanced ser2 phosphorylated Pol II
and elevated transcripts after drug treatment
indicating successful elongation. In addition, a
decrease of the epigenetic regulator LSH in a
breast cancer cell line by siRNA treatment reduced
DNA methylation and overcame Pol II stalling,
whereas overexpression of LSH in a normal breast
epithelial cell line increased DNA methylation and
resulted in repression. Decrease of LSH was
associated with reduced DNMT3b binding to
promoter sequences, and depletion of DNMT3b by
siRNA could release Pol II suggesting that DNMT3b
is functionally involved. The release of paused Pol II
was accompanied by a dynamic switch from repres-
sive to active chromatin marks. Thus release of Pol
II stalling can act as a mechanism for gene
reactivation at specific target genes after DNA
demethylating treatment in cancer cells.
INTRODUCTION
DNA packaging in chromatin regulates access of
DNA-binding factors and ultimately controls transcrip-
tion (1,2). The position and turnover rate of nucleosomes,
histone modiﬁcations, cytosine methylation and recruit-
ment of chromatin remodeling factors all determine chro-
matin structure and affect the transition of a repressed
inactive state to an open active state that allows transcrip-
tion. The recruitment of RNA polymerase II (Pol II) to
the promoter is regarded as one of the rate-limiting steps
in gene activation (3). Another level of transcriptional
control involves the transition of the Pol II initiation
complex into the elongation phase that leads to full-length
transcripts, a process known as release of paused/stalled
Pol II, and ﬁnally, Pol II termination has to complete the
process. Each phase of transcription requires speciﬁc
modiﬁcations of the Pol II itself, recruitment of different
supportive factors, speciﬁc chromatin changes and can be
independently modulated (2–5). Genome-wide studies
revealed that 20–50% inactive genes can be occupied
by Pol II around promoter–proximal regions, but do not
lead to full-length transcripts (6). A recent study reported
that the transcription factor c-myc controls transcription
in ES cells by interfering with the pausing factors DISF
and NELF, thus resulting in a release of paused Pol II at
target genes (7). Thus, Pol II activity in humans is also
effectively regulated at the level of elongation (8).
Silencing of tumor suppressor genes in human cancer is
frequently associated with DNA methylation of the
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lished and maintained by a family of DNA
methyltransferases (11). DNMT3a and DNMT3b are
able to establish novel DNA-methylation patterns and
DNMT1, residing at the replication fork and interacting
with PCNA, is primarily thought to maintain cytosine
methylation on the newly synthesized DNA strand. In
addition, several factors have been reported to affect
DNA-methylation patterns during development, among
them the SNF2 factor mammalian LSH (PASG,
HELLS, SMARCA6) and its close Arabidopsis thaliana
homolog DDM1 (11). LSH has been shown to control
de novo DNA methylation of retroviral sequences during
in vitro cell cultures, and to regulate DNMT3b access and
DNA methylation at multiple endogenous loci during de-
velopment (12–16).
DNA methylation can lead to gene silencing by a
variety of reported mechanisms involving, for example,
methyl–DNA-binding proteins, changes in histone acetyl-
ation or inhibition of DNA-binding factors, and well as
repositioning of nucleosomes thus preventing Pol II initi-
ation (17,18). While any type of repressive mechanism
leads ultimately to the same outcome, namely reduced
protein levels, each phase of transcription involves
distinct associated factors and chromatin modiﬁcations
(4,5,19,20). Further understanding which phase of Pol II
activation is inhibited at DNA-hypermethylated genes in
cancer may have the potential to identify novel molecular
targets and may help in the design of effective cancer
therapies.
MATERIALS AND METHODS
Cell culture
The immortalized human mammary epithelial cell line
(MCF10A), and breast cancer cells (MCF7 and
MDA-MB-231) were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA). For
5-Azacytidine treatment, cells were treated with 1mM
5-Azacytidine (Sigma) for 5 days prior to RNA, DNA,
protein and chromatin isolation. Nature products
(–)Epigallocatechin gallate (EGCG), Parthenolide and
Quercitrin Hydrate were purchased from Sigma. The
cells were treated with 20mM of EGCG, 10mMo f
Parthenolide and 20mM of Quercitrin for 7 days respect-
ively prior to RNA and chromatin isolation.
RNA interference in MDA-MB-231 cells
For siRNA interference experiments, two techniques have
been used: For ‘transient’ knockdown, MDA-MB-231
cells were transfected with 100nM of siRNA oligonucleo-
tides of human LSH siRNA (siLSH) or DNMT3b siRNA
(siDNMR3b) or control siRNA (siCTRL) using
Dharmafect Duo Transfection Reagent. The ‘transient’
knockdown experiments used SMARTpool of four oligo-
nucleotides for 72h and the sequences and source code
(Dharmacon) of all oligonucleotides are listed in
Supplementary Table S1. For ‘stable’ knockdown of
LSH, a shRNA lentivirus set of ﬁve clones (RHS4533-
NM_018063 from Openbiosystems) was used and stable
expressing cells selected with 1mg/ml of puromycin. Cells
that had been transfected with the empty control vector
pLKO.1 served as control cells. The sequences of the
ﬁve hairpins are available on the company’s webpage
http://www.openbiosystems.com. The cDNA clone for
full-length human LSH was obtained from
Openbiosystems (Clone ID:4109340) and ligated into
pMXs (CellBioLabs) and transfected into MCF10A
cells. Cell lysates were prepared for further analysis after
72h.
Western analysis
Equal amounts of protein (20–50mg) were separated on
4–12% Bis–Tris SDS–PAGE (Invitrogen) and transferred
onto a nitrocellulose membrane.
PCR analysis
For RT–PCR analysis, total RNA was extracted using
Qiagen RNeasy Mini Kit and 2mg were reverse
transcribed with 50ng random primers and 10U Reverse
Transcriptase (Superscript III Kit, Invitrogen). The
cDNA was diluted 1:10, and 2ml were used for analysis.
Results were normalized for expression of the housekeep-
ing gene Gapdh. For Real-time PCR analysis, primers for
qPCR were designed using primer 3.0 software with an
optimal annealing temperature of 60C. The sequences
of primers and probes are listed in Supplementary Table
S1. Gene expression was normalized relative to GAPDH
using Delta–Delta CT. Experiments were performed in
triplicates and summarize two to four independent
experiments.
ChIP and MeDIP analysis
ChIPs were performed as previously described (21).
Speciﬁcally, for detection of H3 modiﬁcations data was
normalized by performing simultaneously ChIP analysis
using anti-H3 antibodies. Real-time PCR analysis was
performed, for each primer the ampliﬁcation efﬁciency
was calculated and the data expressed as enrichment
related to Input. Before carrying out MeDIP, 10mg
genomic DNA was sonicated to size from 200 to 700bp.
Fourmicrograms of gel puriﬁed DNA was used for a
MeDIP assay as described previously (14).
Antibodies
The following antibodies were used: normal mouse or
rabbit IgG (Upstate), rabbit anti-LSH recombinant
protein afﬁnity-puriﬁed antibody (15); detection of
hypophosphorylated Pol II by 8WG16 (ab817), detection
of ser5 phosphorylated Pol II by H14 (ab24759), detection
of ser2 phosphorylated Pol II (ab5095), JARID1A/RBP2/
KDM5A(ab45301), anti-H3 (ab1791), anti-H3 (tri methyl
K4) (ab8580) (Abcam) and anti-Ezh2 (ab3748);
5-Methylcytidine (BI-MECY-0100)(Eurogentec);
anti-b-actin (A2228)(Sigma); anti-DNMT3b (ALX-804-
233-C100)(Alexis Biochemicals); anti-CHD1 (NB100-
60411) (Novus Biologicals Inc). Antibodies used
included Anti-acetyl-Histone H4 (06-866), Anti-acetyl-
Histone 3 (06-599), anti-tri-methyl-histone H3 (Lys 9)
Nucleic Acids Research, 2011,Vol.39, No. 22 9509(07–442) and anti-trimethyl-histone H3 (Lys 27) (05–851),
anti-SUZ12 (07-379) all from Upstate Biotechnology
(Lake Placid, NY, USA).
Cell-growth curve, soft agar assay and wound healing
assay
For cell-growth analyses, cells were seeded in 6-well plates.
Cells were trypsinized, collected in triplicate, and counted
each day by trypan-blue staining for eight consecutive
days. Cells suspended in 0.35% agar (1.510
4 cells/
dish) were layered on top of 1ml solidiﬁed agar (0.7%)
in a 35mm dish. DMEM growth medium with a ﬁnal
concentration of 10% FBS was included in both layers.
After 28 days of incubation, colonies were counted.
Experiments were carried out in triplicates. Wound
healing assays were performed in triplicates using
cytoselect 24-well wound healing assay (Cell Biolabs,
Inc.) according to the manufacturer’s instructions.
RESULTS
DNA demethylation is associated with release of Pol II
stalling
To understand more about the molecular mechanisms
involved in transcriptional silencing associated with
DNA methylation, we ﬁrst screened for gene reactivation
after treatment with the DNA demethylating drug
Azacytidine using the non-invasive breast adenocarcin-
oma cell line MCF7 and the invasive, metastatic breast
adenocarcinoma cell line MDA-MB-231. The
non-tumorigenic breast epithelial cell line MCF10A
served as positive control for ‘normal’ tissue. Out of 26
genes that had been previously reported to show signs of
DNA hypermethylation in breast cancer tissue and/or
breast cancer cell lines (10,22), we found 23 to be
affected by Azacytidine treatment in both breast cancer
cell lines albeit to differing extents (data not shown). Five
Azacytidine-inducible genes were selected for further
analysis ranging from highest induction of gene expression
in MCF7 or MDA-MB-231 cells (10- to 46-fold for
CLDN6 and VGF) to moderate effects (3- to 8-fold for
RIN1, MAL, PRA) (Figure 1A). In contrast, treatment of
the breast epithelial cell line MCF10A with Azacytidine
had only a minimal effect on gene expression, suggesting
that DNA methylation plays rather a critical role in the
expression of those selected genes in breast cancer cell
lines than in normal tissue (Supplementary Figure S1).
Using MeDIP analysis, DNA methylation was evident in
a region within 1-kb upstream of the transcriptional start
site (TSS) in the breast cancer cells, but not in the control
MCF10A cell line (Figure 1B and C), consistent with the
selective effect of this drug on gene expression in cancer
cell lines, as opposed to MCF10A (Supplementary Figure
S1). Azacytidine treatment reduced cytosine methylation
in MCF7 and MDA-MB-231 cells effectively (Figure 1B).
These changes of DNA methylation in the upstream TSS
region were further conﬁrmed using bisulﬁte sequencing
(Supplementary Figure S2A) and DNA methylation
sensitive restriction enzymes followed by Real-time
PCR analysis (Supplementary Figure S2B,C).
DNA-methylation changes were only signiﬁcant in the
upstream region of TSS, since the immediate region
around the TSS showed little if any DNA methylation
in untreated cells when bisulﬁte sequencing
(Supplementary Figure S3A) or MeDIP analysis was per-
formed (Supplementary Figure S3B). Thus, gene expres-
sion showed an inverse relationship with DNA
methylation upstream of the TSS region in breast cancer
cell lines for those selected genes.
To address the question whether Pol II stalling is
involved in transcriptional silencing, we examined the
presence of Pol II levels using ChIPs. Pol II is recruited
to promoter regions and undergoes several modiﬁcations
at the C terminal domain (CTD) of its large subunit at
various stages of transcription (2,3). In the pre-initiation
complex, CTD is hypophosphorylated during initiation
the CTD becomes phosphorylated on serine 5 (ser5) and
during elongation Pol II shows phosphorylation on ser2.
Since stalled genes have been shown to have high occu-
pancy of ser5 phosphorylated Pol II at the TSS, but not at
the gene body, we ﬁrst examined association of ser5 Pol II
(19,23). As expected, Pol II occupancy was detected
around the TSS (Region 1) after Azacytidine treatment
(Figure 2A–C). However, Pol II was also present at the
TSS in untreated cancer cells, indicative of a Pol II initi-
ation complex despite repressed transcript levels.
Untreated cells as well as Azacytidine-treated cells
showed signs of histones H3 and H4 acetylation
(Supplementary Figure S4), a mark closely associated
with Pol II levels (6). In contrast, occupancy of ser5
phosphorylated Pol II was distinct at the gene body
(Region 2 located 600-bp downstream of TSS)
(Figure 2A–C). While untreated cells showed low or
barely detectable Pol II association, Azacytidine-treated
MCF7 and MDA-MB-231 cells were enriched for Pol II
consistent with the presence of increased transcript levels.
A similar proﬁle for Pol II levels was observed in MCF7
or MDA-MB-231 cells when using a distinct anti-Pol II
antibody recognizing primarily the hypo-phosphorylated
form of Pol II (Supplementary Figure S5). Recently, a Pol
II stalling index was computed forming the ratio of Pol II
association at the TSS over the association at the gene
body by using a mixture of anti-Pol II antibodies (ser5
phosphorylated and hypophosphorylated) (19,23). We
also assessed the stalling index using data derived from
ser5 phosphorylated Pol II ChIPs and found it varying
between 1 and 3.5 for Azacytidine-treated samples or
varying between 12 and more than 100 in untreated
cells, indicating a clear change in the ratio of Pol II
levels. Finally, we addressed directly the question if
Azacytidine-treated cells show a shift from stalling to suc-
cessful elongation and examined the association of the
ser2 phosphorylated Pol II, a modiﬁcation which is
directly linked to the polymerase elongation activity
(2,3). As shown in Figure 2D, this form of Pol II was
present toward the end of the transcriptional unit
(Region 3) and its association was increased after
Azacytidine treatment in MDA-MB-231 cells compared
to untreated cells. Furthermore, the degree of ser2
phosphorylated Pol II was at levels comparable to those
in MCF10A cells. Taken together, our data suggest that a
9510 Nucleic Acids Research, 2011,Vol.39, No. 22paused Pol II engages at the TSS of repressed genes with
DNA hypermethylation in their upstream region, and
DNA demethylation after Azacytidine treatment is
associated with a release of Pol II stalling, successful
elongation and an increase in transcript levels.
As natural products such as (–)-epigallocatechin-3-
gallate (EGCG), Parthenolide and Quercitrin hydrate (a
quinoline-based compound) can block DNA
methyltransferase 1 activity, and reactivate tumor sup-
pressive genes via DNA demethylation (24–26), we
asked whether these products can overcome Pol II
stalling at those selected genes in breast cancer cell lines.
After treatment of MCF7 and MBA-MD-231 cells for 7
days with various natural products, mRNA expression for
all genes were upregulated in MCF7 (Supplementary
Figure S6A) and MDA-MB-231 cells (Supplementary
Figure S6B). To conﬁrm an effect on DNA-methylation
CLDN6, MAL, RIN1 and VGF were examined by
cytosine methylation sensitive restriction enzymes
followed by Real-time PCR analysis. Signiﬁcant DNA
demethylation was found after treatment with natural
products (Supplementary Figure S6C). ChIP analysis
detected a change in the Pol II stalling index using ser5
phosphorylated Pol II after 7 days of treatment in
MDA-MB-231 cells (Figure 2E) indicating that DNA
demethylating natural products, similar to Azacytidine
treatment, could release Pol II stalling at repressed genes
in breast cancer cells.
AB C
Figure 1. DNA demethylation at selected genes in breast cancer cell lines. (A) RT–PCR analysis for detection of the indicated tumor suppressor
genes using total. RNA derived from MCF7 and MDA-MB-231 cells treated with mock (DMSO) or 5-Azacytidine (AZA). MCF10A cells served as a
positive control. The level of gene expression was normalized against the housekeeping gene GAPDH and is represented as fold changes compared to
MCF10A. We selected Claudin-6 (CLDN6), Myelin and lymphocyte protein (MAL), Prolactin receptor-associated protein (PRA), Ras interaction/
interference protein 1 (RIN1) and VGF nerve growth factor. (B) MeDIP analysis for detection of methylated DNA in a region within 1kb upstream
of TSS. After treatment of MCF7 or MDA-MB-231 cells with Azacytidine (or mock treatment), methylated DNA was immunoprecipitated using
anti-methyl-cytosine antibody (5-mC) and the indicated genes were detected by PCR analysis. Untreated MCF10A served as negative control.
(C) Schematic ﬁgures for primer sites at indicated genes according to the UCSC genome browser (2009 GRCh37/hg19). Validation region a:
Region used for restriction enzyme-based PCR analysis, MeDIP analysis (upstream region), LSH association and DNMT3b binding; validation
region b: Bisulﬁte sequencing region at upstream regions; validation region c: Pol II detection region 1, bisulﬁte sequencing, MeDIP (TSS) and ChIP
analysis around TSS; and validation region d: Pol II detection region 2.
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polycomb proteins and repressive histone modiﬁcations
A high percentage of DNA-methylated cancer genes are
pre-marked with H3K27me
3 modiﬁcations and show
binding of PRC (polycomb repressive complex) compo-
nents (27). Moreover, polycomb target genes have been
demonstrated to contain Pol II stalling when silenced
(20,21). To characterize chromatin changes associated
with Pol II stalled promoter regions, we examined the
presence of polycomb proteins EZH2 and SUZ12. Both
proteins were found associated at the selected Azacytidine
inducible genes in untreated cells and showed overall
reduced association after Azacytidine treatment
(Figure 3A to D). For comparison, ChIPs extracts were
also examined for association of EZH2 and SUZ12
with the polycomb targets RUNX3 and ESR1 (28,29)
(Figure 3A to D, right panel) and EZH2 association was
found to be in a comparable range at those targets. The
dissociation of SUZ12 in MCF7 cells was modest
compared to MDA-MB-231 cells, suggesting the possibil-
ity of a distinct role of this PRC2 component at different
stages of cancer. The EZH2-mediated histone modiﬁca-
tion H3K27me
3 was signiﬁcantly reduced after
Azacytidine treatment (Figure 3E and F). In addition,
the repressive histone mark, H3K9me
3, which is frequent-
ly associated with DNA hypermethylation in adult cancers
was examined (30). Though not commonly found
together, H3K9me3 and H3K27me3 modiﬁcations can
occur simultaneously, in particular, at key developmental-
ly regulatory factors (31). Also, a subset of polycomb
target genes have been found to be occupied by the
histone methyltransferase SetDB1 catalyzing H3K9me3
modiﬁcations (32). H3K9me
3 was also reduced in both
cell lines after Azacytidine treatment (Figure 3G and H).
Taken together, these ﬁndings indicate that the release of
Pol II stalling is associated with reduced DNA methyla-
tion at upstream TSS regions, a reduction of polycomb
proteins and a loss of repressive histone modiﬁcations.
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Figure 2. Pol II stalling at genes with DNA-methylated upstream regions. (A) Schematic representation of the primer positions used for Pol II ChIP
analysis. TES, transcriptional end site. (B and C) ChIP analysis of mock- or Azacytidine-treated MCF7 cells (B) and MDA-MB-231 cells (C) for
detection of ser5 phosphorylated Pol II at the TSS. The histogram shows enrichment values (percentage bound to input) at the TSS (Region 1) or at
the gene body (Region 2) of the indicated genes. (D) ChIP analysis of mock- or Azacytidine-treated MDA-MB-231 and MCF10A cells for detection
of ser2 phosphorylated Pol II linked to the polymerase elongation activity. The histogram shows enrichment values (percentage bound to input)
toward the end of the transcriptional unit (Region 3) of the indicated genes. (E) ChIP analysis for detection of ser5 phosphorylated Pol II (bound/
input) at the TSS of indicated genes comparing mock-treated MDA-MB-231 cells with cells treated for 7 days with natural products EGCG,
Parthenolide (Path) and Quercitrin (Quer). Error bars indicate the range between duplicate ChIPs. The histogram is representative of two similar
biological repeats.
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3 and
CHD1
Next, we monitored the acquisition of active chromatin
marks that are associated with the release of Pol II
stalling. H3K4me
3 was detected prior to DNA
demethylation at all selected genes and was notably
increased after Azacytidine treatment (Figure 4A and B).
For comparison, we also examined the level of H3K4me
3
in MCF7 or MDA-MB-231 cancer cells at the transcribed
gene PCNA (Figure 4A and B, right panel). In addition,
the level of H3K4me
3 modiﬁcation at those genes was
comparable to levels found in the control cell line
MCF10A (Supplementary Figure S7). The modiﬁcation
H3K4me
3 has been shown to serve as a binding domain
for CHD1, a euchromatic protein that interacts with tran-
scriptional elongation factors and thus is capable to
promote the elongation phase of transcription (33). We
detected increased association of CHD1 around the TSS
(except MAL) after Azacytidine treatment, consistent with
the release of Pol II stalling and the enhanced transcript
levels (Figure 4C and D). Next, we examined for the
presence of the H3K4me
3 demethylase JARID1A (34).
AB
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Figure 3. Reduced binding of polycomb proteins after Azacytidine treatment. ChIP analysis for detection of EZH2 around the TSS comparing mock
and Azacytidine-treated MCF7 (A) and MDA-MB-231(B) cells. The polycomb target genes RUNX3 and ESR1 served as positive control for genes
targeted by polycomb proteins. ChIP analysis using rabbit IgG alone served as control (mean values are shown). ChIPs analysis for detection of
SUZ12 comparing chromatin derived from mock and Azacytidine-treated MCF7 (C) and MDA-MB-231(D) cells. The ratio of H3K27me
3 enrich-
ment to total H3 occupancies in MCF7 (E) and MDA-MB-231 (F) cells comparing mock and Azacytidine-treated cells. The ratio of H3K9me
3
enrichment to total H3 occupancies in MCF7 (G) and MDA-MB-231 (H) cells comparing mock and Azacytidine-treated cells.
Nucleic Acids Research, 2011,Vol.39, No. 22 9513This histone demethylase has been reported to mediate
transcriptional repression of polycomb targets by modu-
lation of H3K4me
3 (34) and, moreover, JARID1A was
shown to occupy promoter regions of genes that are
involved in cell-cycle control (35). Concurrently with
H3K4me
3 changes, the binding of JARID1A was
reduced after Azacytidine treatment (except MAL in
MCF7) suggesting that at least part of the H3K4me
3
increase may be due to a reduction of this H3K4-speciﬁc
demethylase (Figure 4E and F). Finally, the ratio of
H3K4me
3 to H3K27me
3 was examined and found to be
greatly increased in MCF7 and MDA-MB-231 cells after
Azacytidine treatment. In particular, ratios in MCF7 cells
were comparable to those in MCF10A cells suggesting a
shift to active chromatin marks (Figure 4G–I). These
ﬁndings suggest that DNA hypomethylation is associated
with a dynamic epigenetic switch that is linked to a release
of Pol II stalling and increased transcript levels.
Reduction of LSH is associated with DNA
hypomethylation and enhanced transcript levels
Our previous studies found that LSH, a member of the
chromatin remodeling family, controls DNA-methylation
levels in mice and is crucial for transcriptional repression
and Pol II stalling at DNA methylated Hox genes (15,21).
Since LSH shows high expression in several human
AB
CD
EF
GH I
Figure 4. Increase in H3K4me
3 modiﬁcations and CHD1 association after Azacytidine treatment. The ratio of H3K4me
3 enrichment to total H3
occupancy at the TSS of indicated genes in MCF7 (A) and MDA-MB-231 (B) cells comparing mock and Azacytidine-treated cells. ChIP analysis
using rabbit IgG alone served as control (mean values are shown). ChIPs analysis for detection of CHD1 comparing chromatin derived from mock
and Azacytidine-treated MCF7 (C) and MDA-MB-231(D) cells. PCNA and LIN28 served as positive control for actively transcribed genes. ChIP
analysis for detection of JARID1A comparing chromatin derived from mock and Azacytidine-treated MCF7 (E) and MDA-MB-231(F) cells. (G–I)
The ratio of H3K4me
3/H3 to H3K27me
3/H3 occupancies in mock and Azacytidine-treated MCF7 (G), MDA-MB-231 (H) and MCF10A cells (I).
9514 Nucleic Acids Research, 2011,Vol.39, No. 22cancers and is upregulated in MDA-MB-231 and MCF7
(Supplementary Figure S8A), we hypothesized that LSH
may play a role in DNA methylation and Pol II stalling in
those cancer cell lines. To generate a transient knockdown
of LSH, MDA-MB-231 cells were treated with siLSH
oligonucleotides (see ‘Materials and Methods’ section)
leading to reduction in LSH protein (Supplementary
Figure S8e) and LSH mRNA expression after 72h
(Supplementary Figure S8C and D). Gene expression
analysis revealed that transient knockdown of LSH
could re-activate CLDN6, PRA, RIN1 and VGF gene
expression while the MAL gene remained repressed
(Figure 5A), suggesting that LSH selectively affects these
genes. MeDIP analysis demonstrated that the transient
knockdown of LSH-reduced DNA methylation at those
genes that were upregulated, whereas the MAL upstream
region still maintained substantial levels of DNA methy-
lation (Figure 5B). Similar to the results obtained by treat-
ment with Azacytidine or natural products, transient
knockdown of LSH also altered ser5 Pol II association,
indicating the release of Pol II stalling (except MAL)
(Figure 5C). Since murine Lsh can stabilize the association
of Dnmt3 to speciﬁc target sites (14,15), we examined the
binding of the DNMT3b protein to upstream regions by
ChIPs analysis. Transient knockdown of LSH resulted in
decreased DNMT3b binding, most notably at those
upstream regions that showed the strongest effect on
cytosine methylation, suggesting that DNMT3b is
involved in DNA methylation at those sites (with the ex-
ception of MAL, Figure 5D). In addition, we performed a
transient knockdown of DNMT3b using siRNA oligo-
nucleotides treatment (Supplementary Figure S9A to D)
to determine if DNA methylation is involved in transcrip-
tional control at those target genes. As shown in Figure
5E, transient knockdown of DNMT3b altered ser5 Pol II
occupancy, further supporting a link between DNA
methylation and Pol II release at those target genes.
Finally, we over-expressed LSH in normal breast epithe-
lial cell line MCF10A, and detected reduced transcript
levels for CLDN6, PRA, RIN1 (Figure 6A). This was
accompanied with slightly increased DNA-methylation
levels (Figure 6B, with the exception of MAL) and a
shift in the ser5 Pol II association, suggesting that the
dynamic modulation of DNA methylation is closely
associated with transcriptional control at those sites.
To understand the physiological role of LSH in breast
cancer, we generated stable LSH knockdown in cancer
cells using a set of shLSH lentivirus vectors (see
‘Materials and Method’ section) and observed a reduction
of LSH protein levels (inlet of Figure 7a and
Supplementary Figure S8b) that was comparable to the
transient LSH knockdown experiments (Supplementary
Figure S8e). Previous analysis had shown that depletion
of Lsh reduces the growth of primary murine ﬁbroblasts
(36). Stable knockdown of LSH resulted in reduced
growth of MDA-MB-231 cells during culture (Figure
7A). Furthermore, stable knockdown of LSH resulted in
a decreased formation of colonies in soft agar colonies
(Figure 7B). Finally, transient knockdown of LSH
impaired migration activity in a ‘wound healing assay’
(Figure 7C), suggesting a physiologic role of LSH
mediated DNA methylation in the growth characteristics
of cancer cells.
DISCUSSION
In this study, we provide evidence for Pol II stalling at
genes with DNA hypermethylated upstream regions and
demonstrate that several cytosine demethylating
approaches, including reduction of LSH or DNMT3b,
Azacytidine treatment or use of natural components are
able to overcome Pol II stalling.
Genome-wide studies have demonstrated that 30–50%
of promoter regions show Pol II occupancy despite the
fact that transcripts cannot be detected (6).
Furthermore, genome-wide analysis revealed that the
majority of TSS sites are free of nucleosomes, and this is
observed at active as well as silenced genes (19). The de-
pletion of nucleosomal regions at TSS is consistent with
Pol II association since removal of nucleosomes is neces-
sary to allow for Pol II association. Recently, it was shown
that immune response genes that were quickly activated by
LPS already showed Pol II association in the uninduced
state (4). Remarkably, those genes, all contained CpG
islands, which are thought to contain intrinsic instability
for nucleosomes (5). Disruption of nucleosomal position-
ing may favor Pol II association before gene induction
occurs.
While Pol II occupancy is generally associated with a
nucleosomal-free region around the TSS, the link between
DNA methylation and nucleosome position is less deﬁned.
Nucleosomal-free regions can be detected at DNA
methylated or hypomethylated TSS indicating DNA
methylation independence for speciﬁc promoter sequences
(18,21). For other regions, DNA methylation can affect
nucleosomal position, either excluding nucleosomes or
enhancing nucleosomal occupancy (18,37), suggesting
that the speciﬁc promoter sequence context is important
for the positioning of nucleosomes. Our data indicate that
DNA methylation in the upstream region within 1kb of
TSS is compatible with Pol II association suggesting a
nucleosomal-free region at the TSS. The TSS sites
appear largely DNA hypo-or unmethylated in untreated
cells, since neither MeDIP analysis nor bisulﬁte sequence
analysis gave much evidence for cytosine methylation. Of
note is that the genes (PRA, MAL, CLDN6, VGF)
examined here contain CpG islands around the TSS that
may contribute to nucleosomal instability and Pol II as-
sociation. Furthermore, histone acetylation was detected
at the TSS, consistent with the observation of Pol II asso-
ciation, since the level of acetylation is thought to support
the formation of a transcription initiation complex (6).
Here, we report Pol II stalling at DNA-
hypermethylated genes in the context of the polycomb
proteins EZH2 and SUZ12 and their speciﬁc mediated
histone mark H3K27me
3. Polycomb proteins have been
shown to control silencing of their target genes, in part,
by Pol II stalling (38). A functional interaction between
polycomb proteins and DNA methylation had been sug-
gested by demonstrating a physical interaction between
DNA methyltransferases and polycomb proteins (39).
Nucleic Acids Research, 2011,Vol.39, No. 22 9515Genome-wide studies demonstrated H3K27me
3 modiﬁca-
tions at DNA-hypermethylated CpG island promoter in
colon cancer (40,41), though not every cancer type shows
this association (42). Several studies have observed DNA
methylation of polycomb target genes during normal de-
velopment or demonstrated aberrant DNA-methylation
pattern of Hox genes in cancer cells. Most importantly,
about half of the analyzed DNMT3b targets are also
bound by PRC complexes, and those genes show
reduced H3K27me
3 levels in ICF patients (that carry
DNMT3b mutations), supporting a direct link between
DNA methyltransferase and polycomb-mediated histone
A
D
BC
E
Figure 5. LSH reduction decreases DNA methylation and reduces Pol II stalling in breast cancer cells. (A) RT–PCR analysis for detection of
indicated genes using total RNA derived from MDA-MB-231 cells that had a transient knockdown of LSH (siLSH) using RNA interference (pool of
four siLSH oligonucleotides) or had received control siRNA oligonucleotides for 72h (siCTRL). Gene expression levels were normalized against the
housekeeping gene GAPDH. (B) MeDIP analysis for detection of methylated DNA at upstream regions using genomic DNA derived from
MDA-MB-231 cells that had a transient knockdown of LSH (siLSH) or had been treated with siCTRL oligonucleotides (siCTRL). (C) ChIPs
analysis for detection of ser5 Pol II association comparing chromatin derived from MDA-MB-231 cells that had a transient knockdown of LSH
(siLSH) or had been treated with siCTRL oligonucleotides (siCTRL). (D) ChIPs analysis for detection of DNMT3b comparing chromatin derived
from MDA-MB-231 cells that had a transient knockdown of LSH (siLSH) or had been treated with siCTRL oligonucleotides (siCTRL). (E) ChIPs
analysis for detection of ser5 Pol II association comparing chromatin derived from MDA-MB-231 cells that had a transient knockdown of DNMT3b
(siDnmt3b) or had been treated with siCTRL oligonucleotides (siCTRL).
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Figure 6. Over-expression of LSH increases DNA methylation and leads to a shift in Pol II association at the TSS in MCF10A cells. (A) RT–PCR
analysis for detection of indicated genes using total RNA derived from MCF10A cells that were either control vector transfected (mock) or
transfected with a LSH expression vector (LSH) for 72h. Gene expression levels were normalized against the housekeeping gene GAPDH.
(B) MeDIP analysis for detection of methylated DNA at upstream regions using genomic DNA derived from MCF10A cells that were mock
transfected (mock) or transfected with an LSH expression vector (LSH). (C) ChIPs analysis for detection ser5 Pol II comparing chromatin derived
from MCF10A cells that were transfected with an LSH expression vector (LSH).
Figure 7. LSH reduction affects growth characteristics of breast cancer cells. (A) Cell growth curve was assessed at indicated time points comparing
the growth pattern of MDA-MB-231 cells with a stable knockdown of LSH (siLSH) and control cells (siCTRL). LSH protein levels as detected by
western analysis are shown in the ﬁgure within. (B) Growth in soft agar was measured in MDA-MB-231 cells with a stable knockdown of LSH
(siLSH) and control cells (siCTRL). Error bars represent SEM. (C) MDA-MB-231 cells with a transient knockdown of LSH were analyzed for their
ability to migrate in a wound healing assay at indicated time points. *P-value <0.01.
Nucleic Acids Research, 2011,Vol.39, No. 22 9517modiﬁcations (43). On the other hand, depletion of
polycomb proteins in leukemic cells can also alter
DNA-methylation level, suggesting several feedback
loops (44). Hox genes that are in part regulated by Lsh
also show Pol II stalling (21). Reduction of Lsh in mice
results in DNA hypomethylation and reduced polycomb
protein binding, and decreased H3K27me
3 and
H2AK116ub levels (15). The epigenetic switch caused by
Lsh reduction leads to a release of Pol II stalling suggest-
ing that at those polycomb targets there exist a functional
link between Lsh-mediated DNA methylation, polycomb
proteins and paused Pol II (21). Furthermore, catalytically
active Dnmt3b is required for Pol II stalling at Hox genes
(21). Finally, reduction of DNA methylation (by RNA
interference of DNMTs) in human colon cancer cells
results in H3K27me
3 loss and reduced binding of PRC
proteins (45). In particular, DNMT3b depletion shows
speciﬁc reduction of H2AK116ub, a histone modiﬁcation
mediated by PRC1 and implied in the process of Pol II
stalling (20,45). Thus, multiple reports point to either a
link of DNA methylation and polycomb proteins, or to
an association of polycomb proteins and Pol II stalling.
The genes that are presented here show the silencing mark
of DNA methylation in association with Pol II stalling.
Although other pathways of transcriptional regulation are
not excluded, our data suggest that the effect of DNA
methylation and LSH on Pol II stalling may in part be
mediated by the presence of polycomb proteins.
The release of Pol II stalling after use of DNA
demethylating drugs, as we report in this study, is
associated with a switch from repressive marks to active
chromatin marks. We observed reduced association of
polycomb proteins, and a decrease in JARID1A binding
(except MAL). JARID1A (RBP2, KDM5A) is a speciﬁc
histone demethylase for di- and tri-methylated H3K4 (46).
JARID1A is associated with a large number of polycomb
target genes, such as Hox genes, and upon differentiation
of ES cells JARID1A is displaced at polycomb target
genes, leading to increased H3K4me
3 and gene transcrip-
tion (34,47). The dissociation of JARID1A with
DNA-hypermethylated genes as observed in this study
may be in part explained by decreased binding of
polycomb proteins. While changes of DNA methylation
may result in increased H3K4me
3 modiﬁcations, reduction
of the H3K4me
3 histone methylase MLL can alter
DNA-methylation levels at polycomb target genes, sug-
gesting a bi-directional link between histone methylation
and DNA methylation (48,49). The rise in H3K4me
3 in
turn may then serve as a recruitment signal for CHD1
since CHD1 has double chromodomains that interact
directly with lysine 4 methylated histone 3 tails (50).
This peptide recognition of CHD1 blocks the site of inter-
action with polycomb proteins thus interfering with
polycomb binding (50). CHD1 is generally found in eu-
chromatin associated with the promoter of active genes
and is required to maintain the open chromatin of pluri-
potent mouse ES cells (51). Additionally, CHD1 through
recruitment of elongation factors as well as splicing factors
to active genes promote elongation and the generation of
mature full-length transcripts (52).
We report here the involvement of LSH in gene repres-
sion and that depletion of LSH overcomes Pol II stalling.
LSH and its A. thaliana homolog DDM1 (decrease of
DNA methylation 1), belong to the chromatin remodeling
SNF2 family that controls DNA-methylation level in mice
and A. thaliana, respectively (13,53). At single-copy genes,
such as Hox genes and at some stem cell genes, dynamic
modulation of LSH in cultured cells can regulate
DNMT3b association and DNA methylation (14,15,21).
However, LSH effects are gene speciﬁc, since most im-
printed genes are not impacted by LSH deletion (54).
Furthermore, depletion of murine or human LSH in cell
cultures leads only to a slow decrease of DNA methylation
at repeat sequences over many passages (55,56), suggest-
ing distinct molecular mechanisms of DNA methylation at
single-copy genes compared to repetitive sequences, the
latter involving piRNA and PIWI proteins (57). In this
study, reduction of LSH resulted in less DNMT3b asso-
ciation, and a decrease in DNMT3b levels in turn, leads to
DNA hypomethylation at those selected sites. Thus, LSH
as well as DNMT3b play a role in preserving the DNA
methylation pattern at those sites. However, since the
effects of transient knockdown of DNMT3b or LSH are
measured not earlier than 72h, we cannot rule out that
some of our observations are secondary effects of these
treatments as opposed to direct effects. Also, it is not
clear, if the requirement for DNMT3b is based on main-
taining DNA methylation at the replication fork, or if
active DNA demethylation occurs at those sites (58) and
DNMT3b preserves the DNA-methylation pattern by
re-establishing cytosine methylation.
LSH is upregulated in several cancers and a few reports
imply the presence of LSH in tumor progression. LSH is
found to be a novel target of FOXM1 and its expression
correlates tightly with human non-small cell lung cancer
progression (59). Additionally, expression signatures
associated with melanoma progression show the
upregulation of LSH (60). A recent report suggests that
LSH is a critical component of the p63 pathway to bypass
senescence in skin cancer cells (61). In acute myelogenous
leukemia and acute lymphoblastic leukemia, LSH tran-
scripts contain an in-frame 75-nt deletion, which is in a
conserved motif known to be critical for the transactiva-
tion activity of a related yeast SWI/SNF polypeptide (62).
Black cohosh that inhibits the growth of human breast
cancer cells is also accompanied by a decrease in LSH
expression (63). Our study provides evidence that LSH
reduction and re-activation of suppressed genes may
lead to an ameliorated aggressive phenotype of
MDA-MB-231 cells, as demonstrated by inhibition of pro-
liferation, reduced anchorage independent growth and a
decrease in cell migration. Since LSH deﬁciency does not
affect DNA methylation of most imprinted sites, which
are effected by inhibition of DNMT1, the targeted
decrease of LSH may bear the potential to support thera-
peutic approaches for re-activation of silenced tumor sup-
pressor genes.
Silencing of tumor suppressor genes through epigenetic
repression is one of the hallmarks of human cancer. LSH
controls DNA methylation and gene repression at some
selected target genes in breast cancer cells. Furthermore,
9518 Nucleic Acids Research, 2011,Vol.39, No. 22we provide evidence that Pol II stalling can mediate
repression at several genes with upstream DNA-
hypermethylated regions in cancer cells. Understanding
the distinct molecular pathways at speciﬁc genomic
targets and identifying novel molecular targets can be
helpful in devising future strategies to reverse epigenetic
gene silencing as supportive cancer therapy.
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